VOLUNTARY ANNOUNCEMENT - INCLUSION OF TQ-B3234 “SELECTIVE MEK1/2 INHIBITOR” IN THE BREAKTHROUGH THERAPY DESIGNATION PROCESS

VOLUNTARY ANNOUNCEMENT - TQB2102 "HER2 BISPECIFIC ADC" INCLUDED IN THE BREAKTHROUGH THERAPEUTIC DESIGNATION PROCESS

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 SEPTEMBER 2025

NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED HOLDERS

NOTIFICATION LETTER AND REPLY FORM FOR REGISTERED HOLDERS

2025 INTERIM REPORT

VOLUNTARY ANNOUNCEMENT - COMPLETION OF ENROLLMENT OF THE FIRST PATIENT IN THE PHASE I CLINICAL TRIAL OF LM-350 "CDH17 ADC" IN AUSTRALIA

VOLUNTARY ANNOUNCEMENT - COMPLETION OF ENROLLMENT OF THE FIRST PATIENT IN THE PHASE I CLINICAL TRIAL OF LM-2417 "NaPi2b/4-1BB BISPECIFIC ANTIBODY" IN CHINA